截至2026年1月9日收盘，佐力药业(300181)报收于16.6元，上涨0.85%，换手率2.18%，成交量13.17万 手，成交额2.17亿元。 董秘最新回复 来自交易信息汇总：1月9日主力资金净流出2815.54万元，游资与散户资金分别净流入1075.85万元 和1739.69万元。 交易信息汇总资金流向 1月9日主力资金净流出2815.54万元；游资资金净流入1075.85万元；散户资金净流入1739.69万元。 投资者： 未来社会是智能化的社会，脑机智能将会占据重要地位，请问贵司对这个方向有哪些战略规 划和储备，谢谢！ 董秘： 您好！公司暂未布局脑机接口领域。感谢您的关注！ 投资者： 近段时间，公司股价与大势背离走，下跌又多，是否公司2025年业绩不达标，没有完成激励 指标？ 董秘： 您好！股价波动受宏观环境及市场情绪等多重因素综合影响，公司将持续做好经营，努力提升 经营效益，切实维护好广大投资者权益和资本市场稳定。感谢您对公司的关注！ 当日关注点 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The current "brain-computer interface" is a market hotspot, attracting significant investor attention, particularly after the company's stock price rose by 6.52% with a trading volume increase of 299% compared to the previous trading day. The company is urged to ensure that disclosures related to this hot topic are accurate and complete to avoid misleading investors [2] Group 1: Regulatory Actions - The Shanghai Stock Exchange issued a regulatory warning to the company, highlighting inconsistencies in the announcement regarding the technical path of its partner and insufficient risk disclosures related to collaboration uncertainties [2] - Following the announcement of a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd., the company faced immediate media scrutiny and market attention [2][3] Group 2: Partnership Details - The company clarified that the current research products of Brain Machine Starlink are based on a non-invasive technical path, with no invasive technology in development, and that some products are still in early research or pre-clinical stages [3] - The company plans to invest no more than 15 million yuan in Brain Machine Starlink, with an estimated research and development investment of around 30 million yuan for the related projects, which are still in early stages and have uncertain development timelines [3] Group 3: Financial Performance - For the first three quarters of 2025, the company's revenue was approximately 1.287 billion yuan, a year-on-year decrease of 7.69%, while net profit was about 60.42 million yuan, down 72.36% year-on-year. The company reported cash and cash equivalents of 465 million yuan [4]

板块热度飙升 Wind数据显示，上周，万得脑机接口概念指数（8841700）大涨18.95%。相关概念股中，创新医疗收获 涨停五连板，南京熊猫、普利特分别录得涨停四连板，美好医疗、三博脑科等也连续4个交易日大涨。 脑机接口板块大涨的背后，是政策、技术、产业与资本的多重利好叠加释放。 2026年开年，脑机接口一跃成为全球科技与资本市场的焦点之一。 近日，特斯拉CEO马斯克宣布，旗下Neuralink公司将于2026年启动脑机接口设备的"大规模生产"，并将 转向"更加精简和几乎完全自动化的外科手术流程"，这一表态也迅速点燃了市场热情。几乎前后脚，国 内脑机接口独角兽企业强脑科技宣布完成了约20亿元融资，规模位居全球第二。 在海外量产预期、国内政策支持与临床突破的多重共振下，A股脑机接口板块掀起了涨停潮。在板块大 涨的这波行情中，提前埋伏其中的基金也明显受益，净值大幅攀升。 脑机接口，这个一度只存在于科幻作品中的概念，正加速走进现实。 政策、技术与资本共振 1月5日，华银健康生活主题灵活配置单日涨幅达11.8%，领跑全市场基金；长城消费增值混合、国泰创 新医疗混合等单日涨幅也超过10%，位居市场前十。根据2025年 ...

Group 1 - Public funds have entered the market with over 45 billion yuan expected by January 10, 2026, driven by new stock ETFs and active funds [1] - The total scale of newly listed stock ETFs is 6.345 billion yuan, while active funds nearing 40 billion yuan are in the accumulation phase [1] - Individual investors are leading the ETF market, with some products having over 90% share from personal investors [1] Group 2 - Over 100 billion yuan flowed into the market through ETFs last week, with a total trading volume of 14.13 trillion yuan in the Shanghai and Shenzhen markets [2] - Stock-type and cross-border ETFs saw a net inflow of 13.14 billion yuan, while broad-based index ETFs experienced a net outflow of 12.9 billion yuan [2] Group 3 - China has submitted applications for an additional 203,000 satellites, primarily from a new agency, the Radio Innovation Institute [3] - The increase in satellite launches is expected to accelerate in 2026, with private commercial rocket companies likely to play a significant role [3] Group 4 - A number of brain-computer interface concept stocks have been heavily researched by institutions, with Entropy Technology receiving the highest number of visits at 136 [4] - Other notable companies include Prilite and Xiangyu Medical, with 127 and 71 institutional visits respectively [4] Group 5 - Shaoyang Hydraulic's stock price surged by 106% over 11 trading days, closing at 58.45 yuan with a market capitalization of 6.367 billion yuan [5][8] Group 6 - In 2025, 89.74% of 9,934 private equity securities products achieved positive returns, with an average return rate of 25.68% [9] - Quantitative long strategies performed exceptionally well, with a 95.81% positive return rate and an average return of 39.51% [9] Group 7 - Tianpu Co. is under investigation by the China Securities Regulatory Commission due to abnormal stock trading, but the company states that its operations remain normal [10] Group 8 - This week, 23 stocks are facing unlocks, with a total market value exceeding 48 billion yuan, including over 10 billion yuan from Zhongke Lanyun [11]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, specifically recommending stocks such as Micro-Invasive Brain Science, Xiangyu Medical, and Meihua Medical [1]. Core Insights - The report emphasizes the focus on brain-computer interfaces (BCI) as a strategic high ground in global technology, supported by national policies and significant investments [5][19]. - It highlights the approval of innovative drugs and therapies, such as the human thyroid-stimulating hormone beta and the HER2-targeted therapies, which are expected to set new standards in treatment [2][3]. - The report ranks sub-industries in terms of investment potential, with innovative drugs at the top, followed by research services, CXO, traditional Chinese medicine, medical devices, and pharmacies [3][12]. Summary by Sections Industry Trends - The A-share pharmaceutical index has increased by 7.81% year-to-date, outperforming the CSI 300 by 5.03% [11]. - The report notes a significant rise in the healthcare sector, with medical services and devices showing strong performance [11]. Policy Support for Brain-Computer Interfaces - The "14th Five-Year Plan" identifies brain-computer interfaces as a key future industry, with a clear policy support from the government [18]. - The National Health Insurance Administration has established pricing standards for BCI procedures, indicating a commitment to support this emerging field [19][20]. R&D Progress and Company Dynamics - The report lists several companies with promising drug pipelines, including those focusing on PD1 PLUS, ADC, and small nucleic acids, suggesting specific stocks to watch [14]. - It provides a detailed overview of recent approvals and clinical trials, indicating a robust pipeline for innovative therapies [2][3]. Market Performance - The report highlights the significant gains in the pharmaceutical sector, with specific stocks like Innovation Medical and Sanbo Brain Science showing remarkable increases [11]. - It also notes the performance of H-shares, with companies like Jinfang Pharmaceutical-B and Shengnuo Pharmaceutical-B leading the gains [11].

Company Overview - Aipeng Medical focuses on medical devices, specializing in pain management and upper airway management, while also exploring brain-computer interface innovations [5] - The company has a strategic partnership with Ruishen'an Medical, a leading player in the neuroregulation field in China [5] Product Competitiveness - The "Multimodal ADHD Behavioral Training System" integrates data connectivity between in-hospital and home training environments, addressing both medication and behavioral training as primary treatment options [6] - The system aims to provide a comprehensive training solution, mitigating risks associated with traditional single behavioral training products [6] Clinical Applications - The Persistent Insomnia Anesthesia Treatment System has been implemented in hospitals, showing promising treatment outcomes and attracting interest from sleep and anesthesia specialists [7] - The company’s EEG collection products are essential components of the ADHD treatment system, with relevant pricing established in various provinces [9] Future Investments - Aipeng Medical plans to continue exploring brain-computer interface opportunities aligned with its strategic direction, focusing on sensor technology, signal processing, and clinical applications for mental health disorders [10] - The establishment of an AI and Brain-Computer Engineering Research Institute aims to drive innovation in pain management, anesthesia, and mental health diagnostics [10] Business Progress of Ruishen'an - Ruishen'an has successfully launched several products, including the implantable vagus nerve stimulator and the rechargeable spinal cord stimulator, generating revenue [11] - The first domestic implantation of a closed-loop neurostimulation system for Parkinson's disease is expected to occur by the end of 2025, marking a significant advancement in clinical practice [11]

证券研究报告|宏观研究报告 [Table_Date] 2026 年 01 月 11 日 [Table_Title] 上涨趋势确立 [Table_Title2] 类权益周报 [Table_Summary] ►回顾：上涨趋势进一步确立 1 月 5-9 日，类权益市场持续上涨。截至 2026 年 1 月 9 日， 万得全 A 收盘价为 6737.75，较 12 月 31 日上涨 5.11%；中证 转债同期上涨 4.45%，偏股型转债估值明显拉伸。 市场开年大涨，标志着指数脱离 10-12 月的震荡区间，中期 上涨趋势确立。同时，中盘品种受青睐，中证 500 和中证 1000 领涨。此外，热门题材不断涌现，包括脑机接口、商业 航天、半导体材料设备等。在上涨趋势进一步巩固的状态 下，资金对安全边际的需求减小，而对弹性和高度更为重 视。 ►策略：保持乐观和耐心 快速上涨之后，市场难免震荡。万得全 A 的 RSI（相对强弱指 标）已上升至 90 以上，提示短期或有波动。不过，上涨趋势 已然确立，不必对前高之上的波动过于敏感。即使行情大幅 震荡（例如 2025 年 7 月 30 日至 8 月 1 日、9 月 2-4 日），市 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Report Industry Investment Rating No relevant information provided. Core Viewpoints - The convertible bond market sentiment is high due to the strengthening of equities and seasonal effects. The equity market rose rapidly after the New Year's Day holiday, and the convertible bond market also performed strongly. The median market price of convertible bonds increased by 5 yuan to 138 yuan, and the valuation continued to rise while the underlying stocks were rising. The premium rates of convertible bonds in each parity range are close to the 100% quantile of historical levels, and the convertible bond ETF shows a significant net inflow trend. Looking forward, due to seasonal effects, some institutions with calendar - year assessments such as annuities and securities dealers' proprietary trading may gradually increase their positions in January. There is still a small room for the valuation of convertible bonds to increase. Relative - return investors are advised to allocate small - position and well - balanced non - redeemable equity - biased convertible bonds with suitable premium rates, and absolute - return investors are recommended to focus on high - volatility underlying stocks below 130 yuan or industry leaders with historically low valuations [2][16] Summary by Relevant Catalogs Market Focus (January 5 - January 9, 2026) Stock Market - A - shares rose rapidly after the New Year's Day holiday, with the Shanghai Composite Index breaking through 4000 points and the daily trading volume reaching nearly 3 trillion yuan. The technology - growth style led the rise, with sectors such as brain - computer interface, commercial aerospace, and controllable nuclear fusion performing well, while the dividend sector lagged behind. By industry, most Shenwan primary industries rose, with the comprehensive (14.55%), national defense and military industry (13.63%), media (13.10%), non - ferrous metals (8.56%), and computer (8.49%) sectors leading the gains, and the banking (-1.90%), transportation (0.23%), petroleum and petrochemical (0.29%), and agriculture, forestry, animal husbandry and fishery (0.98%) sectors performing poorly [1][6][7] Bond Market - At the beginning of the year, the central bank continued to conduct net withdrawals in the open market, but the capital market remained generally balanced and loose. Affected by the continuous rise of the equity market and the strong performance of the commodity market, the bond market was generally weak in shock. The 10 - year Treasury bond yield closed at 1.88% on Friday, up 1.98bp from the previous week [1][7] Convertible Bond Market - Most convertible bond issues rose last week. The CSI Convertible Bond Index rose 4.45% for the whole week, the median price rose 3.60%, and the arithmetic average parity calculated by the report rose 5.79%. The overall conversion premium rate decreased by 0.55% compared with the previous week. In terms of individual bonds, the convertible bonds of Seli (AI medical), Dingjie (AI application), Dinglong (semiconductor), Shengxun (AI security), and Borui (innovative drugs) led the gains, while those of Tianchuang (control right change), Dianhua (solid - state battery), Huarui (CNC cutting tools & announced forced redemption), Huanxu (sip module & announced forced redemption), and Maolai (precision optics) led the losses. The total trading volume of the convertible bond market last week was 468.504 billion yuan, with an average daily trading volume of 93.701 billion yuan, an increase from the previous week [1][7][11] Views and Strategies (January 12 - January 16, 2026) - The convertible bond market sentiment is high under the strengthening of equities and seasonal effects. The equity market rose rapidly after the New Year's Day holiday, and the convertible bond market also performed strongly. From the data of convertible bond holders in December, public funds and social security funds increased their positions, while the positions of insurance and annuity institutions reached the lowest level since 2022, and the reduction of securities dealers' proprietary trading has slowed down. Looking forward, due to seasonal effects, some institutions may gradually increase their positions in January, and the convertible bond valuation still has a small room for improvement. Relative - return investors are advised to allocate non - redeemable equity - biased convertible bonds with suitable premium rates in small positions, and absolute - return investors are recommended to focus on high - volatility underlying stocks below 130 yuan or industry leaders with historically low valuations [2][16] Valuation Overview - As of January 9, 2026, for equity - biased convertible bonds, the average conversion premium rates of convertible bonds with parities in the ranges of 80 - 90 yuan, 90 - 100 yuan, 100 - 110 yuan, 110 - 120 yuan, 120 - 130 yuan, and above 130 yuan are 51.34%, 41.94%, 29.84%, 26.12%, 23.41%, and 17.71% respectively, located at the 99%/100%, 98%/100%, 96%/99%, 99%/100%, 98%/100%, and 99%/100% quantiles since 2010/2021. For debt - biased convertible bonds, the average YTM of convertible bonds with parities below 70 yuan is - 4.06%, located at the 2%/5% quantiles since 2010/2021. The average implied volatility of all convertible bonds is 50.47%, located at the 96%/100% quantiles since 2010/2021. The difference between the implied volatility of convertible bonds and the long - term actual volatility of the underlying stocks is 9.41%, located at the 97%/100% quantiles since 2010/2021 [17] Primary Market Tracking - Last week (January 5 - January 9, 2026), Lianrui Convertible Bond announced its issuance, and no convertible bonds were listed. The underlying stock is Lianrui New Materials, a leading company in the basic chemical industry. The scale of the convertible bond issuance is 695 million yuan, and after deducting the issuance fees, it is planned to be used for high - performance high - speed substrate ultra - pure spherical powder material projects, high - thermal - conductivity high - purity spherical powder material projects, and supplementary working capital. As of the announcement on January 9, there are no convertible bonds announced for issuance or listing in the next week. Last week, there was 1 new company approved for registration by the exchange (Naipu Mining Machinery), 1 new company accepted by the exchange (Shangluo Electronics), and 4 new companies with board proposals (Quanxin Co., Ltd., Fujia Co., Ltd., Yilian Technology, Zhenhua Co., Ltd.). As of now, there are 97 convertible bonds to be issued, with a total scale of 150.27 billion yuan, including 7 approved for registration with a total scale of 8.34 billion yuan and 5 approved by the listing committee with a total scale of 2.91 billion yuan [24][25]

Core Insights - The ETF market has shown significant performance in technology growth styles, particularly in sectors like brain-computer interfaces, AI applications, commercial aerospace, and semiconductors, with notable market profitability [1][2]. Group 1: Commercial Aerospace ETFs - The commercial aerospace theme ETF, specifically the Yongying National Satellite Communication Industry ETF (159206.SZ), saw a net inflow of 35.89 billion yuan, leading the market in ETF fund inflows [2]. - The Zhaoshang Zhongzheng Satellite Industry ETF (159218.SZ) recorded a net inflow of 13.79 billion yuan, tracking the satellite industry index with major components including China Satellite and Aerospace Electronics [2]. - The funding logic is driven by policy catalysts, technological breakthroughs, and order placements, indicating a high prosperity cycle for the sector [2]. Group 2: Brain-Computer Interface ETFs - The Yongying Zhongzheng All-Index Medical Device ETF (159883.SZ) experienced a net inflow of 14.41 billion yuan, with over 23% of its components related to brain-computer interfaces [2]. - The funding logic is supported by announcements from Neuralink regarding large-scale production of brain-computer interface devices and the inclusion of brain-computer interfaces in China's 14th Five-Year Plan [2]. Group 3: AI Application ETFs - The GF Zhongzheng Media ETF (512980.SH) saw a net inflow of 8.73 billion yuan, focusing on gaming applications related to brain-computer interfaces [3]. - The Huaxia Zhongzheng Animation Game ETF (159869.SZ) also reported a net inflow of 8.23 billion yuan, benefiting from AI cost reduction and efficiency improvements [3]. Group 4: Semiconductor ETFs - The Guotai Zhongzheng Semiconductor Material Equipment Theme ETF (159516.SZ) had a net inflow of 23.18 billion yuan, focusing on AI computing power upstream core targets [4]. - There is a structural differentiation within the semiconductor theme ETFs, with inflows into material equipment and outflows from chip sectors [3]. Group 5: Overall ETF Market Trends - The industry theme ETFs had a net inflow of 138.27 billion yuan over the past week, while broad-based index ETFs experienced a significant net outflow of 129.01 billion yuan, indicating a preference for sector-specific investments [5][9]. - The market is witnessing a divergence in valuations, with major broad-based indices at historical highs while certain sectors, like Hong Kong stocks, are attracting inflows due to lower valuations [7][9].